**Name of Journal: *World Journal of Hypertension***

**ESPS Manuscript NO: 22895**

**Manuscript Type: Review**

**RhoA signaling and blood pressure: The consequence of failing to “Tone it Down”**

Bai X *et al*. RhoA and blood pressure control

**Xue Bai, Rachel Dee, Kevin D Mangum, Christopher P Mack, Joan M Taylor**

**Xue Bai, Rachel Dee, Kevin D Mangum, Christopher P Mack, Joan M Taylor,**Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States

**Author contributions:** Bai X, Rachel Dee R and Mangum KD contributed equally to this work; all authors contributed to literature review and analysis, drafting and critical revision and editing, and approval of the final version.

**Supported by** the National Heart, Lung, and Blood Institute, National Institutes of Health to Taylor JM, Nos. HL-081844 and HL-071054; and the Muscular Dystrophy Association to Taylor JM, No. MDA255577.

**Conflict-of-interest statement:** No conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Joan M Taylor, PhD,** Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, CB7525, 501 Brinkhous-Bullitt Bld, Chapel Hill, NC 27599, United States. jmt3x@med.unc.edu

**Telephone**: +1-919-8435511

**Fax**: +1-919-9666718

**Received:** September 30, 2015

**Peer-review started:** October 8, 2015

**First decision:** November 6, 2015

**Revised:** November 24, 2015

**Accepted:** January 21, 2016

**Article in press:**

**Published online:**

**Abstract**

Uncontrolled high blood pressure is a major risk factor for heart attack, stroke, and kidney failure and contributes to an estimated 25% of deaths worldwide. Despite numerous treatment options, estimates project that reasonable BP control is achieved in only about half of hypertensive patients. Improvements in the detection and management of hypertension will undoubtedly be accomplished through a better understanding of the complex etiology of this disease and a more comprehensive inventory of the genes and genetic variants that influence BP regulation. Recent studies (primarily in pre-clinical models) indicate that the small GTPase RhoA and its downstream target, Rho kinase, play an important role in regulating BP homeostasis. Herein, we summarize the underlying mechanisms and highlight signaling pathways and regulators that impart tight spatial-temporal control of RhoA activity. We also discuss known allelic variations in the RhoA pathway and consider how these polymorphisms may affect genetic risk for hypertension and its clinical manifestations. Finally, we summarize the current (albeit limited) clinical data on the efficacy of targeting the RhoA pathway in hypertensive patients.

**Key words:** Hypertension; Blood pressure; RhoA; Smooth muscle contraction; Guanine nucleotide exchange factor; GTPase activating protein; Polymorphisms

© **The Author(s) 2016**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Studies (primarily in pre-clinical models) indicate that the small GTPase RhoA and its downstream target, Rho kinase, play an important role in regulating BP homeostasis. Herein, we summarize the underlying mechanisms and highlight signaling pathways and regulators that impart tight spatial-temporal control of RhoA activity. We also discuss known allelic variations in the RhoA pathway and consider how these polymorphisms may affect genetic risk for hypertension and its clinical manifestations. Finally, we summarize the current (albeit limited) clinical data on the efficacy of targeting the RhoA pathway in hypertensive patients.

Bai X, Dee R, Mangum KD, Mack CP, Taylor JM. RhoA signaling and blood pressure: The consequence of failing to “Tone it Down”. *World J Hypertens* 2016; In press

**INTRODUCTION**

Although hypertension is a major risk factor for stroke, myocardial infarction, and kidney failure and contributes to over 350000 deaths annually in the United States[1], we know surprisingly little about its development or the mechanisms by which it promotes cardiovascular disease. A number of antihypertensive drugs are available, but regimens are usually chosen empirically and multiple drugs that target different organ systems are frequently required for effective treatment. One reason for these difficulties is that blood pressure (BP) is a complex trait that is regulated by many organ systems and a large number of humoral factors. Thus, a better understanding of the molecular and genetic mechanisms that control BP under normal and pathologic conditions should lead to novel drug targets and/or to personalized therapies that are more effective and less toxic. Recent advances suggest that RhoA signaling plays a role in the development human hypertension. The focus of this review will be (1) to highlight the mechanisms underlying RhoA-dependent regulation of BP; (2) to discuss how allelic variations in the RhoA signaling pathway affect genetic risk for hypertension and its clinical manifestations; and (3) to summarize the current (albeit limited) clinical data on the efficacy of targeting this pathway in hypertensive patients.

As a critical regulator of the actin cytoskeleton and acto-myosin contractility, the small GTPase, RhoA, regulates a variety of cellular processes including force development, endocytosis, exocytosis, adhesion, migration, proliferation, and differentiation[2]. Like all GTPases, RhoA is regulated by GTP binding and cycles between the active GTP-bound form and the inactive GDP-bound form. When GTP-bound, RhoA interacts with a variety of effector molecules that mediate its effects on the actin cytoskeleton including the Rho-associated coiled-coil domain containing protein kinases (ROCK I and II), the diaphanous-related formins (mDia1 and mDia2), protein kinase N, citron kinase, rhophilin, and rhotekin. With respect to regulation of BP, Rho kinases are arguably the most important effectors as evidenced by the findings that increased ROCK activity has been observed in spontaneously hypertensive rats and some hypertensive patient populations[3,4] and ROCK inhibitors like Y-27632, Fasudil, and SAR407899 have been shown to reduce BP in hypertensive animal models and patients[5].

**RHOA SIGNALING AND BP REGULATION**

BP homeostasis is tightly controlled by many organ systems and humoral factors that regulate peripheral vascular resistance, sodium and water balance, and cardiac output. Below we summarize the role RhoA signaling in the regulation of BP highlighting recent findings that implicate this pathway in the development of hypertension.

***Rho A and arteriole tone***

Vascular resistance is a major determinant of BP and is controlled, in large part, by smooth muscle cell (SMC) contraction within small peripheral arterioles[6-10]. Excitation-contraction coupling in SMC is mediated by the Ca2+-dependent activation of myosin light chain kinase (MLCK), and SMC tension is directly proportional to myosin light chain (MLC) phosphorylation as this enables myosins molecular interaction with actin[11,12]. Interestingly, besides promoting an increase in intracellular Ca2+, many GPCR-coupled contractile agonists including angiotensin II (AII), norepinephrine, and endothelin-1 (ET1) also stimulate RhoA activity in SMC and in intact arteries[3,4,13]. Active RhoA leads to Rho-kinase (ROCK)-dependent inhibition of myosin phosphatase and results in elevated MLCK activity and enhanced sensitization to Ca2+ [3,14-16]. Importantly, several studies in animal models and patients (described in further detail below) indicate that RhoA-dependent pathways are involved in the increased vascular resistance associated with hypertension[3-5,13,17].

Active RhoA also induces *de novo* formation of actin filaments that are necessary for force development and SMC contraction. Rho-dependent actin remodeling occurs by both ROCK-dependent and independent processes. The Rho effectors mDia 1 and 2 directly catalyze actin polymerization in cooperation with the actin binding protein, profilin, whereas ROCK stimulates actin polymerization by inhibiting the disassembly of actin polymers through LIM-kinase-dependent inhibition of cofilin (ROCK activates LIM-kinase 1 and LIM-kinase 2 by phosphorylation at threonine 508 or 505 respectively within the activation loop[18,19]). ROCK also phosphorylates ezrin-radixin-moesin (ERM) proteins which enhances their tethering to integral PM proteins and promotes actin filament stabilization[20].

The Rho effectors mDia 1 and 2 directly catalyze actin polymerization in cooperation with the actin binding protein, profilin, whereas ROCK stimulates actin polymerization by inhibiting the disassembly of actin polymers through LIM-kinase-dependent inhibition of cofilin (ROCK activates LIM-kinase 1 and LIM-kinase 2 by phosphorylation at threonine 508 or 505 respectively within the activation loop;[18,19,21,22]). ROCK also phosphorylates ERM proteins which enhances their tethering to integral plasma membrane proteins and promotes actin filament stabilization[23].

Recent studies indicate that RhoA signaling also controls SMC contractile gene expression by regulating the nuclear translocation of the Myocardin-related transcription factors (MRTF-A and MRTF-B). Under conditions of low RhoA activity, monomeric (G)-actin binding to the MRTF N-terminus masks a nuclear localization sequence resulting in cytoplasmic sequestration of these serum response factor (SRF) co-factors. The fall in cytoplasmic G-actin levels that occurs upon RhoA-mediated actin polymerization promotes MRTF nuclear accumulation and promotes the expression of SM -actin, SM-actin, SM myosin heavy chain, calponin, and SM22[24,25]. Thus, not only does RhoA control SMC contractility, but it also regulates the levels of the SMC-specific contractile proteins that support this function. Moreover, elevated RhoA in endothelial cells impairs endothelial cell-mediated vasorelaxation as it decreases availability of the potent vasodilator, nitric oxide by reducing both eNOS expression and activity[26-30]. In sum, signaling through RhoA enhances Ca2+ sensitivity, promotes actin remodeling and induces expression of contractile proteins and these responses are necessary for maintaining sustained SMC contractility and elevated vessel tone (Figure 1).

***RhoA and kidney function***

The kidneys play a major role in regulating BP by controling sodium excretion and blood volume. In addition, since the kidneys are highly perfused organs receiving up to 25% of total cardiac output, increased contracility of renal arterioles can significantly increase total peripheral vascular resistance. In most vascular beds, arteriolar tone is controlled by automic innervation and circulating hormones. However, in pre-glomerular afferent arterioles, increased kidney perfusion (manifesting as increased renal BP) stimulates SMC contraction through the tubuloglomerular feedback and myogenic responses (see[31] for review). The former mechanism is mediated by increased glomerular filtration and NaCl delivery from the loop of Henle to the macula densa (MD), a cluster of epithelial cells located at the junction between the distal convoluted tubule and the end of the thick ascending limb and adjacent to the abluminal SMCs of the afferent arterioles. Increased NaCl uptake by MD cells results in secretion of ATP and adenosine which stimulate afferent arteriole SMC contraction *via* P2Y4/P2Y6 and A2 GPCRs, respectively. The myogenic response is mediated by the activation of stretch-sensitive cation channels. Together these mechanisms stabilize renal blood flow to protect the sensitive glomerular capillaries from flow-induced trauma. Importantly, afferent arterioles express Rho A, ROCK I and II[32], and several studies have convincingly demonstrated that the Rho/Rho kinase pathway influences both of these feedback mechanisms in response to increased kidney perfusion[33-37]. The requirement of RhoA is likely due, at least in part, to its necessity for P2Y4/P2Y6 and A2 receptor-dependent contractility. Indeed, ATP (*via* P2Y4/Y6) and adenosine (*via* A2) stimulate RhoA activity in SMC and their pressor responses were prevented by pretreatment with the Rho-kinase inhibitor, Y-27632[32].

Interestingly, recent evidence indicates that RhoA may play an additional role in other cell types within the kidney to impact volume homeostasis. In particular, RhoA activity in tubular epithelial cells can regulate sodium reabsorption and excretion primarily by altering the density and location of epithelial sodium channels (ENaCs) and the sodium-hydrogen exchanger (NHE3)[38]. *In vitro* studies in cultured epithelial cells indicated that the Na+ current through ENaCs was significantly increased by expression of wildtype or constitutively active RhoA (G14V) and supressed by expression of dominant negative RhoA (T19N). The changes in current correlated with alterations in the density of ENaCs at the PM[39] and mechanistic studies determined that RhoA signaling was essential for intracellular vesicle mediated transport of ENaCs to the apical cell surface[40,41]. RhoA signaling also regulates the activity and subcellular localization of NHE3, a key regulator of sodium absorption in the proximal convoluted tubule. NHE3 associates with ezrin and cortical actin filaments at the plasma membrane and treatment with either the RhoA inhibitor, diarrheal toxin toxin B, or Y-27632 disrupted these interactions and promoted the internalization of NHE3 to sub-membrane compartments[42,43]. Moreover, Nishiki *et al*[44]showed that spontaneously hypertensive rats exhibited elevated NHE3 activity and a exagerated level of Na+ reabsorption when compared to normotensive controls and that Na+ reabsorption was normalized by treatment of the hypertensive animals with Y27632.

***RhoA in the central and peripheral nervous system***

The central nervous system (CNS) constantly assesses pressure levels in the vasculature and makes necessary signaling adjustments to prevent BP variability. The main mechanism by which the CNS monitors BP is through a rapid negative feedback loop termed the baroreceptor reflex. Baroreceptors are sensory neurons located primarily in the aortic arch and carotid sinuses that continuously respond to pressure-induced streching of the vessels in which they reside. Impulses from baroreceopters are relayed *via* glossopharyngeal and vagus nerves to the nucleus tractus solitarii in the brainstem[45], which in turn relays the signal to the rostral ventrolateral medulla[46] and increases or decreases parasympathetic and sympathetic stimulation to the heart and vessels accordingly. Interestingly, the CNS component of this feedback loop has been shown to be dependent on RhoA/Rho-kinase signaling. Rho-kinase inhibitors microinjected directly into the NTS or infection of this structure with an adenovirus expressing a dominant-inhibitory form of Rho-kinase reduces sympathetic nerve activity, heart rate, and BP in normotensive rats and these effects are even more pronounced in spontaneoulsy hypertensive rats[47,48]. Moreover, infusing the ROCK inhibitor, Y27632, into the neural cistern attenuated the BP increase that resulted from AII infusion into the same area of the brainstem[49].

Recent studies indicate that the RhoA pathway may also regulate neurotransmitter release from perivascular nerves. Yamaguchi *et al*[50] found that Gα12/13-mediated activation of RhoA/ROCK inhibited Ca2+ dependent exocytosis. In support of these studies, an activating mutation in ArhGEF10, a RhoGEF highly expressed in the peripheral nervous system, was identified in pateints who exhibited slowed nerve conduction velocities[51,52]. Thus, it is possible that RhoA's ability to block neurotransmitter release in peripheral nerves could affect vascular tone and BP, although this effect would likely decrease total peripheral resistence and BP.

While RhoA’s effects on the CNS are clear, a heretofore understudied area in this field is the extent to which RhoA regulates neurotransmitter release from the perivascular nerves which are known to play a major role in the control of resistance arteriole tone. While it has long been known that RhoGTPases have an important and conserved function in mediating neuronal survival and death and that tight spatiotemporal control of RhoA is necessary for appropriate neuronal development (neurite outgrowth, growth cone dynamics) and regeneration, to our knowledge no studies have explored the consequence of Rho-kinase inhibition on peripheral nerve structure or function. Future studies to this end are warranted, because some studies in cells and invertebrate model systems indicate that Rho/Rho kinase signaling may limit the release of sympathetic (contractile) agents and promote the release of parasympathetic relaxation factors from motor neurons. For example, Yamaguchi et al found that G12/13-mediated activation of RhoA/ROCK inhibited Ca2+ dependent exocytosis of the contractile neurotransmitter dopamine in PC12 cells[50]. In support of these studies, an activating mutation in ArhGEF10, a RhoGEF highly expressed in the peripheral nervous system, was identified in pateints who exhibited slowed nerve conduction velocities[51,52]. On the other hand, Hiley *et al*[53] reported that release of the relaxation neurotransmitter, acetylcholine from cholinergic motor neurons in C. elegans, required the regulators of g protein signaling (RGS)-RhoGEF dependent activation of Rho A. Thus, it is formally possible that inhibition of RhoA in perpheral nerves could lead to an increase total peripheral resistance and BP. This concept requires further exploration if RhoA/ROCK inhibitors are to be considered as future anti-hypertensive therapies.

***RhoA in the myocardium***

Several studies have shown that RhoA signaling has direct effects on cardiac function that increase cardiac output and BP. Transgenic mice that overexpressed either GDI or dominant negative RhoA exhibited conduction defects and cardiomyocytes isolated from these mice exhibited decreased L-type Ca2+ channel currents that likely contributed to the decreased contractility observed *in vivo*[54,55]. Vlasblom *et al*[56]showed that treatment of neonatal ventricular cardiomyocytes with Y27632 reduced the expression and activity of the sarcoplasmic reticulum Ca2+ Atpase, SERCA2a, thereby limiting the amount available for Ca2+ -induced Ca2+ release in the next cardiac cycle. In addition, RhoA-dependent pathways have been shown to be critical for phosphorylation and sensitization of cardiac troponin T complex to intracellular Ca2+ levels[57]. Moreover, while not initially thought to be a major mechanism for modulating cardiac contractility, it is becoming clear that cardiac MLC phosphorylation can enhance muscle contractility by increasing Ca2+ sensitivity[58] and that MLC phosphatase is a target for Rho kinase-dependent inhibition in the myocardium (like in SMC). Indeed, Lauriol et al[59] showed that cardiac-restricted deletion of RhoA led to decreased contractility and this effect was correlated with decreased MLC activity. Other similarities between RhoA signaling in cardiomyocytes and SMC include the ability of RhoA-mediated signals to promote differentiation/maturation by promoting the expression of contractile genes[60].

**CONTROL OF RHOA GTPASE ACTIVITY**

Rho proteins act as molecular switches that cycle between an inactive GDP-bound form and an active GTP-bound form and this cycle is under the direct control of three groups of regulatory proteins. Guanine dissociation inhibitors (GDIs) sequester RhoA into an inactive cytoplasmic fraction, guanine nucleotide exchange factors (GEFs) activate RhoA by facilitating exchange of GDP for GTP, and GTPase activating proteins (GAPs) promote RhoA’s intrinsic GTPase activity to hydrolyze GTP to GDP and efficiently turn off (or tone down) RhoA-dependent signaling. The GEF and GAP protein families are quite large and structurally diverse and it is likely that additional differences in expression patterns and post translational modification allow for tissue-specific and tight spatio-temporal control of RhoA activity. The following section summarizes the known mechanisms for controlling RhoA activity in SMC.

***RhoGEFs and BP control***

GEFs activate small GTPases by increasing the GDP dissociation rate by several orders of magnitude which in turn promotes GTP-binding since GTP is in an approximately 10:1 molar excess to GDP in mammalian cells[61]. To date, over 24 different Rho-selective GEFs have been identified. The common functional domain of RhoGEFs is the Dbl homology (DH) domain (also refered to as the RhoGEF domain), which typically serves as both the catalytic site and the major binding interface for RhoA (Figure 2). A pleckstrin homology (PH) domain is almost always found downstream of the DH domain and this unit serves to facilitate membrane binding and cooperates with DH domains to fully activate RhoA[62]. Other common functional domains include the RGS domain that binds large G-proteins to couple the GPCR and Rho signaling pathways and the Postsynaptic Density 95, disk large, Zona occludens-1 (PDZ) domain that binds to Plexin-B1 and Lysophosphatidic Acid (LPA) Receptor to transmit Semaphorin 4D (57) and LPA signals[63], respectively.

The major contractile agonists that stimulate RhoA activity in SMC include AII, phenylephrine (PE), ET1, and thromboxane A2. The GPCRs for these ligands couple to various Gα subunits, including Gα12/13 and Gαq/11, but each has distinct Gprotein coupling properties. For example, PE signals almost exclusively through Gαq and thromboxane through Gα12/13 while other agonist-receptor interactions lead to more promiscous G protein activation. These heterotrimeric GTPases in turn either directly or indirectly activate a range of RhoGEFS. Therefore, it is likely that each agonist could stimulate somewhat overlapping but distinct set of RhoGEFS to enable fine tuning of the extent and duriation of Ca2+ sensitization and thus engender precise spatial and temporal control of vessel tone.

RGS family of Rho GEFs (LARG, p115RhoGEF, and PDZRhoGEF)[64] has received a lot of attention in the BP field because these proteins can interact with (and be directly activated by) Gα12 and Gα13[65]. Indeed, activaiton of RhoA by many of the aforementioned contractile agonists is mediated, at least in part, by these RhoGEFs. However, studies performed in mice lacking the a subunits of Gαq/11 or G12/13 in smooth muscle convincingly showed that activation of these RhoGEFs are not simply due to direct binding to G12/13 [13]. In fact G12/13 depletion did not affect the pressor effects of AII, or PE, and only modestly reduced the pressor effects of ET1. Instead, depletion of Gq/11 completed abrogated PE-induced pressor responses and dramatically attenuated responses to AII. Subsequent studies from Guilluy *et al*[13] identified p115RhoGEF (p115) as the critical GEF that mediates AII-dependent RhoA activity in SMC and small arterioles and showed that smooth muscle specific deletion of p115 rendered mice resistant to AII-dependent hypertension. Interestingly, their mechanistic studies confirmed that p115 activation did not require Gα12/Gα13, but instead, was governed by Gq -mediated, Janus tyrosine kinase-dependent phosphorylation of Tyr738 in the PH domain. Importantly, phosphorylation mimetic and deficient variants at Tyr738 elevated and reduced p115's GEF activity, respectively[13]. As discussed in further detail below, phosphorylation-dependent activation of RhoGEFs has since emerged as a critical regulatory pathway. However, it should also be noted that AII–dependent activation of RhoA in SMC likely involves additional pathways as AII signaling in SMC has been linked to inhibition of p190Rho GTPase activating protein (see below[66]; upregulation of LARG[67], upregulation of PDZ-RhoGEF[68], and Gq/Ca2+/ proline-rich tyrosine kinase 2 (PYK2) tyrosine kinase mediated phosphorylation/activation of PDZ-RhoGEF[69]. Indeed, Ying *et al*[69] showed that Ca2+/PYK2-dependent activation of PDZ-RhoGEF was necessary for maximal AII induced RhoA activation.

Interestingly, p115 mutant mice also exhibited a partial reduction in DOCA/salt-induced hypertention but had normal basal BP and normal pressor responses to ET1 and PE; agents that also act through Gq-dependent signaling pathways. Future studies are necessary to determine how PE and ET1/Gq signals differ from those induced by AII. However, recent studies by the Somlyo laboratory shed some light on this phenomena as they found that there is functional overlap between p115 and LARG. Indeed using genetic mouse models, they found that while the time it took to reach maximal contraction was increased in SMC-specific double knockouts, maximal contraction of smooth muscle from PDZ-RhoGEF and LARG double knockdown tissues was similar to that of the single mutants[70]. Thus it is formally possible that AII (but not ET1 and PE) induced hypertension is blocked by p115 knockout because AII has a relatively reduced capacity to activate LARG. Interestingly, Medlin et.al. identified the vasoconstrictor agonist sphingosine-1-phosphate (S1P) as a potent activator of LARG in cultured vascular SMC[71]. While this pathway has not yet been confirmed *in vivo* the finding that LARG knockout mice are resistant to salt-induced hypertension [4] which leads to volume overload-induced stretching of vessels is consistent with the thesis that LARG may regulate RhoA activity and SMC contractility in response to mechanical forces[72].

Besides activation of the RGS GEFs, several studies have linked Gq/11-dependent activation of RhoA to the Trio family of Rho GEFs (Trio, Duet, and p63RhoGEF)[73,74]. P63-RhoGEF is highly expressed in arterial smooth muscle and it has recently been shown to be important for the early phase of AII-dependent vessel contractilily[75] and for maximal pressor response to other vasoconstrictors such as PE and ET1 that act through Gq/11[76]. Moreover, another non-RGS Rho GEF termed lymphoid blast crisis (Lbc) has been shown to be critical for serotonin-dependent activation of RhoA and contractility in vascular SMC[77]. In summary, specific vasoconstrictors can lead to activation of distinct but overlapping sets of RhoGEFs (each with different activation kinetics, catalytic activities, and subcellular locales). A question that warrants further studies is to what extent GEFs might also govern control over the activation of specific RhoA effector subsets by various agonists.

Like p115, PDZRhoGEF and LARG are also activated by tyrosine phosphorylation. Focal adhesion kinase (FAK) as well as its related family member, PYK2 phosphorylate PDZRhoGEF[69,78], while LARG was shown to be activated by FAK[78] and Tec[64,69]. Future identification of the specific sites of phosphorylation will aid in determining if there is a conserved mechanism by which these modifications promote GEF activity.

Control of RhoGEF expression is another important means of regulating RhoA activity in the vasculature. Because p115-RhoGEF, PDZ-RhoGEF, and LARG each play a role in BP regulation in rodents, it is no surprise that these GEFs are expressed in both conductance and resistance arteries of rats and mice[4,68,69,79]. P63RhoGEF is also abundant in the peripheral vasculature[80]. Interestingly, the expression of many of these RhoGEFs fluctuates as BP changes, suggesting that dynamic regulation of their expression is important for BP control. The most comprehensive study performed to date revealed that expression of each of the five RhoGEFs linked to Rho-A dependent vasoconstriction (p115, LARG, PDZ-RHOGEF, p63 RhoGEF, and lbc) are all down-regulated in cultured mesenteric artery SMC following treatment with AII for 48 h. Moreover, treatment with the Rho Kinase inhibitor fasudil prevented the AII-induced expression of p115, LARG and PDZ-RhoGEF indicating that RGSRhoGEF expression is governed, at least in part, by negative-feedback signaling through the Rho/Rho kinase cascade. A similar decrease in RGSRhoGEF expression was observed in mesenteric arteries from rats treated with AII for 14 d[80]. Whether Rho-GEF expression is altered in or contributes to hypertension in animal models is less clear. Ying *et al*[81]reported that aortic expression of all 3 RGSRhoGEFs was higher in aortas from 12 wk old SHR than in normotensive rats. Similarly, a comprehensive microarray analysis revealed that LARG expression was upregulated in DOCA-salt hypertensive mice [82]. In contrast, Hilgers *et al*[68]reported that mesenteric arteries from 14 d AII-treated rats exhibited decreased mRNA levels, but increased protein levels of PDZ Rho-GEF. Thus, while it is clear that GEF expression is dynamic, the extent to which elevated expression of these factors contributes to the induction of hypertension and reduced expression to BP normalization is currently unresolved and requires further study.

***RhoGAPs and BP control***

GAPs inhibit Rho signaling by enhancing the intrinsic ability of Rho to hydrolyze GTP[83, 84]. More than 70 RhoGAPs have been identified in eukaryotes that can be divided into 23 subfamilies[85]. Like the RhoGEFs, RhoGAPs are typically large multi-domain containing proteins and their diverse structures allow for dynamic and selective inhibition of small GTPase signaling (see Figure 2). Several Rho-selective GAPs including p190ARhoGAP, ArhGAP1, Myr5, GRAF1, and GRAF3 have been shown to regulate RhoA in cultured vascular SMC[86,87].

To our knowledge, GRAF3 is the only RhoGAP that has been implicated in the regulation blood pressure. The founding member of the GRAF (GTPase Regulator Associated with FAK-1) family, was originally identified by our group[88-90] by screening an embryonic λgt11 expression library for proteins that interacted with the carboxyl-terminal domain of FAK [88]. The GRAF family's three members are defined by an N-terminal BAR (Bin/amphiphysin/Rvs) domain, a phosphatidylserine (PS)-binding PH domain, a central Rho-GAP domain, a serine/proline rich domain, and a C-terminal SH3 domain (Figure 1A). The GRAF1 SH3 domain was shown to specifically bind to a proline-rich region in the carboxy terminus of FAK and this protein-protein interaction was important for directing GRAF1 to the actin cytoskeleton[88]. GRAF1 is expressed predominantly in the brain and striated muscle (cardiac and skeletal), and our studies in GRAF1-depleted *Xenopus* and mice revealed that GRAF1-dependent inhibition of RhoA activity promoted mammalian muscle growth by facilitating myoblast fusion and injury repair [90-93]. GRAF2 is more ubiquitously expressed[94] and could partially compensate for the loss of GRAF1 during myotube formation supporting at least some functional redundancy within this family [92]. Evolutionarily, GRAF3 is the youngest family member and is the most recently annotated. Interestingly, our genome wide analyses of chromatin structure in primary human SMC suggested that this gene was regulated in a smooth muscle-specific fashion. Indeed, we found that GRAF3 was highly and selectively expressed in SMC with particularly high expression in resistance vessels [87]. After validating that GRAF3 functioned as a RhoA-specific GAP in these cells, we considered the possibility that GRAF3 might control BP homoeostasis. Importantly, we found that homozygous GRAF3 knockdown mice showed a consistent and significant elevation in systolic, diastolic, and mean arterial BP (+20-30 mmHg). The observation that heterozygous GRAF3 knockdown mice exhibited a 15 mmHg increase in BP strongly supports a dose-dependent relationship between GRAF3 expression and BP. GRAF3-deficient mice exhibited significantly elevated pressor responses following treatment with AII, ET1, or PE and these effects were inhibited by treatment of GRAF3 deficient mice with Y-27632. Accordingly, RhoA activity and myosin light chain phosphorylation were elevated in GRAF3-depleted SMC *in vitro* and *in vivo*[87].

The remarkable SMC-selective expression pattern of this Rho-selective GAP when coupled with the ability of ROCK inhibition to normalize the hypertensive phenotype of GRAF3-deficient animals strongly supports a model in which GRAF3 plays a major role in regulating BP homeostasis by limiting RhoA-mediated SMC contractility in resistance vessels[87]. Interestingly, as discussed in further detail below, a large GWAS revealed that polymorphisms in the GRAF3 gene contribute to BP variation in humans[95,96]. Thus future studies that strive to determine the mechanisms that control variations in GRAF3 expression and/or activity will likely lead to important insights into how to better control BP in the general population.

P190RhoGAP may also play a role in limiting RhoA-dependent arterial tone. p190RhoGAP contains an amino-terminal GTP-binding domain, a large middle domain with multiple protein–protein interaction motifs (diphenylalanine, FF motifs) a polybasic region, and a carboxy-terminal GAP domain[97]. Knockdown of p190RhoGAP in SMC by siRNA increased RhoA/Rock activity[98], and several studies have shown that p190RhoGAP is activated by phosphorylation of Y1105 by cAbl and Src tyrosine kinases[66, 99]. p190RhoGAP is a substrate for the tyrosine phosphatase, SHP-2, and SHP-2-dependent dephosphorylation of p190RhoGAP was shown to be important for the initial burst in RhoA activity in SMCs treated AII and ET1[98]. Interestingly, ROCK-dependent phosphorylation at Ser1150 attenuated p190RhoGAP activity creating a positive feedback loop for further RhoA activation[86]. Phosphorylation of several C-terminal residues by ERK also suppresses p190RhoGAP activity during focal adhesion formation[100]. Finally, although not yet shown in SMC, p190RhoGAP has also been shown to be regulated by phospholipid binding[101]. Additional studies will be necessary to determine if p190RhoGAP plays an important role in BP regulation *in vivo*.

***Regulation of GDIs***

GDIs bind to GDP-bound GTPases and inhibit GDP dissociation. GDI binding also limits translocation of GTPases to the membrane effectively“locking“ them in the inactive state. Indeed, studies have shown that GDIs can inhibit RhoA dependent Ca2+ sensitization in SMCs treated with α-adrenergic and muscarinic agonists[102]. However, the extent to which RhoGDIs regulate BP or RhoA activity *in vivo* is unclear. One study showed that RhoGDIα knock out mice displayed a salt-dependent increase in BP, but this effect was attributed to an increase in Rac1 activity in the kidney[103]. However, since SMC-specific Rac1 knockout mice were hypertensive and exhibited increased RhoA activity, it will be important to measure RhoA and Rac1 activity in SMC in RhoGDIα knock out mice[104]. RhoGDIs have been shown to bind to and regulate RhoGEFs and RhoGAPs [105], an effect that could indirectly influence RhoA activity and vessel tone. Thus, additional studies will be needed to assess RhoGDIs’ role in RhoA dependent blood pressure regulation.

***Direct regulation of RhoA***

Additional control of RhoA signaling may be imparted by mechanisms that alter RhoA protein levels and/or alter functional post-translational modifications. Notably, protein ubiquitination followed by proteasome-dependent degradation is a major means of fine-tuning protein levels and Chen *et al*[106]reported that RhoA is a direct target of the Rho-BTB/Cullin-3 E3 ubiquitin ligase degradation pathway. Interestingly, the Sigmund laboratory found that Cullin-3 regulated vascular smooth muscle function and arterial BP through a RhoA/Rho-kinase pathway. Moreover, they found that a human hypertension-associated mutation in Cullin-3 in which exon 9 is deleted led to decreased Cullin-3 activity and reduced ubiquitin-mediated Rho A degradation [107,108] (see below for further discussion of these and other genetic variants that influence RhoA signaling and human hypertension). Ubiquitination-dependent regulation of RhoA is also catalyzed by a distinct E3 ubiquitin ligase termed SMAD ubiquitin regulatory factor (Smurf1)[109,110]. Interestingly, Smurf1-dependent degradation of RhoA in endothelial cells has been linked to the development of cerebral cavernous malformation (CCM) a disease that is accompanied by hyperpermeable blood vessels in the brain. CCM results from the homozygous inactivating mutations in one of three *ccm* genes. Crose *et al*[109] demonstrated that *ccm2* bound directly to Smurf1 and that this interaction regulated RhoA degradation, likely explaining the common biochemical defect of elevated RhoA/ROCK signaling and increased permeability observed in *ccm* mutant endothelial cells[109, 110]. Whether this class of E3 ligases regulates RhoA in levels in SMC is currently unknown.

Signaling *via* nitric oxide and reactive oxygen species may add another level of spatial/temporal control of RhoA signaling in the vasculature. Levels of ROS increase in the vasculature under a number of pathological conditions including hypertension, and ROS-mediated activation of RhoA has been demonstrated in vascular smooth muscle [81]. Interestingly, Aghajanian *et al*[111]have demonstrated that ROS can mediate direct activation of RhoA by reversible oxidation of reactive cysteines C16/C19 and that this acts in a similar fashion to GEFs in that it leads to nucleotide displacement and increased GTP binding. Because oxidation of RhoA does not impair RhoGEF binding it is possible that ROS-dependent oxidation might prime RhoA for vasoconstrictor-dependent activation. In contrast, the reactive vasodilator, NO has been shown to inhibit RhoA activation *via* post-translational modification. For example, treatment of SMC with the pharmacological NO donor, PAPA-NONOate promoted RhoA S-nitrosylation that reduced GTP binding and therefore inactivated RhoA[112]. NO signaling may also limit RhoA activity in SMC by promoting cGMP-dependent phosphorylation of RhoA on sites that attenuate membrane targeting (and activation) of RhoA[113, 114]. However, the role that such post-translational modifications play in vivo has yet to be explored.

In summary, RhoA activity in SMC can be dynamically regulated by transcriptional and post-translational mechanisms that alter RhoA protein, its activators, and its inhibitors. Collectively these mechanisms play an important role in precise spatial-temporal control of vessel tone and BP homeostasis. Importantly, while several RhoA GEFs have been shown to be necessary for development of vasoconstrictor-induced hypertension, our recent results in GRAF3-depleted mice demonstrated for the first time that GAP-dependent control of RhoA activity in SMC contributes to the maintenance of basal BP[87].

**GENETIC REGULATION OF THE RHOA PATHWAY IN HUMAN HYPERTENSION**

Hypertension is a devastating disease associated with significant morbidity and mortality due to detrimental pressure-related effects on the kidneys, heart, lungs, brain, and peripheral vasculature. Hypertension affects roughly 80 million people (approximately 32.6% of adults) in the United States alone and was predicted to be primarily responsible for 25% of deaths worldwide in 2010[115]. Despite the fact that nearly 70 drugs (from 15 distinct classes of compounds) are approved for treatment of hypertension in the United States, estimates project that reasonable BP control is achieved in only about half of hypertensive patients. This reality coupled with recent projections that the incidence of hypertension will increase to about 41% in the US by 2030, indicate the urgent need for better screening and treatment modalities[116]. Improvements in the detection and management of hypertension will undoubtedly be accomplished through a better understanding of the complex etiology of this disease.

One way to better predict patient response to therapy is to gain a more comprehensive understanding of the genes and genetic variants that influence BP regulation. Recent projections indicate that up to 60% of BP variation can be explained by genetic factors, but that no single gene exerts a principal effect. Thus, BP is considered to have a complex non-Mendelian mode of inheritance. Indeed a combination of classic positional cloning strategies in families with numerous affected members combined with more recent population-based GWAS studies have led to the identification of 25 rare mutations and 53 SNPs that are predicted to contribute to BP control[117]. The aim of this section of is to highlight variants that impinge on the expression or activity of members of the RhoA signaling axis.

***RhoA-related forms of monogenic hypertension***

Virtually all known cases of monogenic hypertension are associated with volume expansion resulting from mutations in genes involved in renal salt handling or hormones that affect mineralocorticoid activity. However, although hypertensive patients with Gordon’s Syndrome (pseudohypoaldosteronism type IIE) present with salt handling abnormalities, the high BP in these patients is caused by an autosomal dominant mutation in the Cullin-3 gene (see above). Interestingly, this E3 ligase helps target RhoA for proteosomal degradation and *in vitro* studies indicate that increased RhoA/ROCK signaling in vascular SMC may also play a role in Gordon’s Syndrome patients[118]. Exclusion of exon 9 abrogates the Cullin-3 dependent interactions between RhoBTB and the E3 ligase and as RhoBTB serves as a chaperone to recruit RhoA to this degradation complex, expression of exon 9-deficient Cullin-3 leads to aberrant RhoA accumulation [107,108].

***SNP/EQTLs in RhoA-signaling molecules***

Because Rho kinases are major RhoA effector proteins and because both animal and human studies have shown that treatment with Rho-kinase inhibiting compounds lowers BP, a number of case-controlled studies were designed to determine if genetic variants in these genes might influence the development of human hypertension. One group examined the effect of ROCK2 genetic variations on BP in 168 pairs of mono- and dizygotic twins. In this study, four variants were identified in ROCK2, the most notable of which was a nonsynonymous SNP in exon 10 that resulted in a substitution of Thr with Asn at amino acid 431. Importantly, the Asn substitution was associated with increased systemic vascular resistance and BP and was predicted to account for 3%-5% of the BP variance between these patients[119]. Another study in which 18 tag SNPs within the ROCK2 locus were genotyped in 586 normotensive controls and 607 hypertensive Caucasian patients identified a haplotype defined by four SNPs (rs965665, rs10178332, rs6755196, rs10929732) that was recessively associated with a lower risk of hypertension (*P* = 0.003). However, a subsequent study in a separate population of 1344 Chinese patients with coronary artery disease and hypertension and 1267 ethnically and geographically matched controls did not find an association between this haplotype and either BP or cardiovascular disease[120, 121]. Thus, future studies are necessary to determine the relevance of these SNPs with respect to BP control in the general population.

Recent studies have implicated artery stiffness in the pathology of HTN and this parameter has been shown to be a valuable predictor of end organ failure[122-126]. Decreased vessel compliance elevates the mechanical load on the myocardium but also increases peripheral pulse-pressure in the microvasculature resulting in tissue damage in high flow organs such as the brain and kidneys. Until very recently, increased vascular stiffness during aging or the development of HTN was thought to result from changes in extracellular matrix content and composition (*i.e.*, elastin degradation, collagen deposition, etc.). However, new studies suggest that the intrinsic mechanical properties of VSMC (including RhoA-dependent formation of force-generating actin filaments, and increased cell adhesion to the extracellular matrix) may also play a role[127,128]. Notably, Liao *et al*[129] identified two SNPs in ROCK2 that were in complete linkage disequilibrium and associated with arterial stiffness in 1483 un-selected patients from a Chinese population in Taiwan. Subsequent, *in vitro* studies revealed that both SNPs were functional. One SNP, rs978906, affected ROCK2 expression by interfering with microRNA(miR)-1183 binding to its 3’UTR, while the other, rs9808232, which was located in a protein-coding region, increased ROCK2 activity [129].

 As noted above, S1P is a major upstream activator of RhoA in SMC and has vasoconstrictive effects *in vivo* [71, 130]. Interestingly, Fenger *et al*[131, 132] assessed the significance of 353 genetic variants contained within exons of genes in the metabolic sphingolipid network. Of these SNPs, 34 and 40 haplotypes were associated with changes in diastolic or systolic pressures respectively in their 2556 subjects. They found that while the BP effects could not be explained by any single gene, several 2-gene interaction pairs were highly correlated with BP variations. S1P is generated from ceramide in a process that involves two critical enzymes ceramidase (ASAH1) and sphingosine 1- kinase (SPHK1) and the most significant of the 2-gene interactions identified were contained in these genes[131, 132], further supporting a role for RhoA signaling in the development of hypertension. It is likely that future gene interaction studies such as these will provide a powerful approach to both predict hypertension risk and possibly inform treatment options.

In the past decade, many GWAS studies have identified common genetic variations in coding and non-coding genomic regions that vary between individuals and are associated with changes in BP and several of these variants occur in genes linked to the Rho signaling cascade. Notably, one GWAS study that used hypertension as a dichotomous trait identified eight loci associated with BP, and two of these variants were located in RhoA-related genes. One of the target genes was the aforementioned RhoBTB1 which functions with the Cullin-3 complex to maintain low RhoA levels[107, 118]. Another SNP was found at the rhotekin-2 (RHTKN) locus. Although rhotekin was one of the first identified RhoA effector molecules (it has high affinity to Rho-GTP and is widely used in pull down assays for activated RhoA[133]), how Rhotekin functions at a cellular level is still unclear. Nonetheless this association is provocative and clearly indicates that future studies are warranted. Two separate GWAS for BP variation and hypertension have identified significant association signals in the RhoA-interacting protein, plekstrin homology domain containing family A member 7 (PLEKHA7)[134,135]. PLEKHA7 is highly expressed in the kidney and heart and localizes on the cytoplasmic surface of adherens junctions, where it interacts with junctional proteins cingulin and paracingulin to regulate the activity of Rho family GTPases, including RhoA[136]. While the functional SNP(s) have yet to be identified, the finding that PLEKHA7 is required for the development of salt-induced hypertension *in vivo*, highlights the functional importance of this RhoA-interacting protein in BP regulation[137].

Finally, two separate GWAS for BP and cardiovascular disease endpoints identified a novel BP associated locus containing two SNPs in perfect linkage disequilibrium (rs633185 and rs604723) within GRAF3 gene (*ArhGAP42*). Both SNPs were associated with a significant reduction in BP with each copy of the minor allele[95,96]. Of extreme importance, as noted above, we reported that mice in which GRAF3 was depleted developed significant hypertension that was RhoA-dependent[87]. Interestingly, the BP locus falls within the first intron of the GRAF3 gene, indicating that one or both SNPs may affect expression of this Rho-GAP and result in altered SMC contractility. Indeed, data within the Genotype-Tissue Expression database indicated that GRAF3 RNA levels in tibial artery samples were 3-fold higher in patients homozygous for the minor T allele compared to patients homozygous for the major C allele (*P* < 1.5e-10; [138]). Moreover, using allele-specific quantitative RT PCR on RNA isolated from human aortic SMC heterozygous at rs604723, we found that the minor T allele was associated with a significant increase in mRNA expression (Mangum and Mack, personal communication) and we identified a novel cis element by which this allele upregulates GRAF3 transcription. To our knowledge, this is only the second functional SNP identified in a GWAS study that has been linked to a causal gene and pathway (the first being rs5068 located within NPPA/B[117].

Collectively, these studies will likely have important implications in the future diagnosis and treatment of hypertension. For example, patients predicted to exhibit aberrantly high levels of RhoA signaling may respond better to anti-hypertensive regimens directly targeting vessel tone, compared to those that target blood volume. Moreover, they reveal that the RhoA signaling axis may provide highly selective targets for the treatment of human hypertension and related cardiovascular sequela.

**PHARMACOLOGICAL REGULATION OF RHOA AND RHO-DEPENDENT PATHWAYS**

Despite the importance of RhoA signaling in the development of hypertension, few treatments are currently available that target this signaling axis. However, some commonly used anti-hypertensives may interfere with RhoA signaling (Figure 3). For example, since RhoA-dependent regulation of vascular tone is a major contributor to AII-mediated increases in BP [13, 139], the highly utilized class of anti-hypertensives that target AII (*i.e.*, ACE inhibitors and AII receptor blockers) may exert some of their BP lowering effects by reducing RhoA activation. Moreover, although used to treat high cholesterol, HMG-CoA reductase inhibitors such as simvastatin and atorvastatin also have anti-hypertensive properties[140] and their BP lowering effects have been attributed to their ability to block RhoA signaling. RhoA is known to be modified by covalent attachment of a geranylgeranyl isoprenyl to a C-terminal Cys, and this modification (which is blocked by simvastatin treatment) is required for membrane localization and activation of RhoA[141].

While not yet included in standard of care treatment for hypertension, several pharmacologic agents have been developed for inhibiting Rho kinases. In general, kinases make good drug targets due to the relative ease of targeting specific molecules to the ATP-binding pockets of these enzymes. To date, most of the Rho kinase inhibitors utilized in animal studies and clinical trials target the ATP-binding pockets of both ROCK isoforms[142-144]. Although not clinically used in the United States, studies abroad provide compelling evidence for the use of this therapeutic approach for BP control. One particularly effective ROCK inhibitor, fasudil, is currently used in Japan to treat cerebral vasospasm and clinical trials determined that fasudil was also effective in decreasing peripheral vascular resistance in hypertensive patients[5]. However, despite their wide use in cells and animal disease models, neither fasudil nor Y-27632 exhibit suitable specificity for a therapeutic as they can inhibit the activity of several other kinases including PKC, PKA, and MLCK, at higher concentrations[145,146]. These compounds also suffer from having short half-lives, which is a highly undesirable attribute of a drug designed to treat a longstanding disease[147]. Thus, there is great need for development of additional potent, yet specific, ROCK inhibitors that can be safely used in patients[148]. While a few such compounds have been developed recently with such attributes[149-153], whether any these compounds exhibit the necessary selectivity and pharmacogenetic profiles required for BP management in patients requires further study. Moving forward, given the importance of RhoGEFs and RhoGAPs in the control of SM contractility and BP, we believe that it will be possible to engineer clinically-relevant small molecule regulators of these enzymes that could be used to develop new and effective anti-hypertensive therapies.

**CONCLUSION: FUTURE POSSIBILITIES FOR PERSONALIZED TREATMENT OF HYPERTENSION**

Current anti-hypertensive therapy is often empirically based and involves multiple drug regimens[154,155]- an approach that is moderately effective at best as it frequently contributes to unwanted side effects and intolerance or non-adherence to medication. Accordingly, more effective and specific anti-hypertensive agents are necessary. Moreover, based on the fact that BP is a highly variable trait among individuals, a better understanding of the genetic mechanisms regulating this disease is critical for a more personalized treatment plan for patients. Given the numerous regulatory and counter-regulatory mechanisms modulating the RhoA axis, this central axis provides an excellent opportunity for identifying genetic biomarkers that correlate with different levels of hypertensive risk and drug responses. Indeed, genetic variations in both upstream activators and downstream mediators of RhoA have been linked to BP regulation (Figure 3). Screening for such variants could potentially be used to tailor more effective individualized treatments. For example, one study showed that the BP lowering effects the ACE inhibitors or the angiotensin receptor blockers were more pronounced in patients carying a GG genotype at the -391 RGS2 (Regulators of G-protein signaling 2) locus when compared to responses in GC or CC genotype carriers- while no differences were observed in the responses to calcium channel antagonists[156]. Although RGS2 is known to couple to ATR1, the underlying mechanism by which these polymorphisms lead to altered sensitivity is currently unknown. Genetic differences in pharmacogenetics also play a role in response to anti-hypertensive agents, for example polymorphisms in the (G-protein coupled receptor kinase 4) gene were associated with reduced BP-lowering effects of the-blocker atenolol[157]. Whether any of the aforementioned Rho-signaling SNPs influence specific responses to or bio-availability of anti-hypertensive treatments remains a critical unexplored question. The clinical utility of targeting the RhoA pathway should also be further explored.

**REFERENCES**

1. **Go AS**, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. *Circulation* 2014; **129**: e28-e292 [PMID: 24352519 DOI: 10.1161/01.cir.0000441139.02102.80]
2. **Heasman SJ**, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. *Nat Rev Mol Cell Biol* 2008; **9**: 690-701 [PMID: 18719708 DOI: 10.1038/nrm2476]
3. **Loirand G**, Pacaud P. The role of Rho protein signaling in hypertension. *Nat Rev Cardiol* 2010; **7**: 637-647 [PMID: 20808285 DOI: 10.1038/nrcardio.2010.136]
4. **Wirth A**, Benyó Z, Lukasova M, Leutgeb B, Wettschureck N, Gorbey S, Orsy P, Horváth B, Maser-Gluth C, Greiner E, Lemmer B, Schütz G, Gutkind JS, Offermanns S. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nat Med* 2008; **14**: 64-68 [PMID: 18084302 DOI: 10.1038/nm1666]
5. **Masumoto A**, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. *Hypertension* 2001; **38**: 1307-1310 [PMID: 11751708 DOI: 10.1161/hy1201.096541]
6. **Cowley AW**. The genetic dissection of essential hypertension. *Nat Rev Genet* 2006; **7**: 829-840 [PMID: 17033627 DOI: 10.1038/nrg1967]
7. **Davis MJ**, Wu X, Nurkiewicz TR, Kawasaki J, Davis GE, Hill MA, Meininger GA. Integrins and mechanotransduction of the vascular myogenic response. *Am J Physiol Heart Circ Physiol* 2001; **280**: H1427-H1433 [PMID: 11247750]
8. **Davis MJ**, Hill MA. Signaling mechanisms underlying the vascular myogenic response. *Physiol Rev* 1999; **79**: 387-423 [PMID: 10221985]
9. **Hall JE**. The kidney, hypertension, and obesity. *Hypertension* 2003; **41**: 625-633 [PMID: 12623970 DOI: 10.1161/01.HYP.0000052314.95497.78]
10. **Lifton RP**, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell* 2001; **104**: 545-556 [PMID: 11239411 DOI: 10.1016/S0092-8674(01)00241-0]
11. **Etienne-Manneville S**, Hall A. Rho GTPases in cell biology. *Nature* 2002; **420**: 629-635 [PMID: 12478284 DOI: 10.1038/nature01148]
12. **Budzyn K**, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. *Trends Pharmacol Sci* 2006; **27**: 97-104 [PMID: 16376997 DOI: 10.1016/j.tips.2005.12.002]
13. **Guilluy C**, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. *Nat Med* 2010; **16**: 183-190 [PMID: 20098430 DOI: 10.1038/nm.2079]
14. **Amano M**, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *J Biol Chem* 1996; **271**: 20246-20249 [PMID: 8702756 DOI: 10.1074/jbc.271.34.20246]
15. **Kimura K**, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) *Science* 1996; **273**: 245-248 [PMID: 8662509 DOI: 10.1126/science.273.5272.245]
16. **Mueller BK**, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. *Nat Rev Drug Discov* 2005; **4**: 387-398 [PMID: 15864268 DOI: 10.1038/nrd1719]
17. **Guilluy C**, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G, Pacaud P. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. *Am J Respir Crit Care Med* 2009; **179**: 1151-1158 [PMID: 19299501 DOI: 10.1164/rccm.200805-691OC]
18. **Ohashi K**, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. *J Biol Chem* 2000; **275**: 3577-3582 [PMID: 10652353 DOI: 10.1074/jbc.275.5.3577]
19. **Sumi T**, Matsumoto K, Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. *J Biol Chem* 2001; **276**: 670-676 [PMID: 11018042 DOI: 10.1074/jbc.M007074200]
20. **Wirth A**. Rho kinase and hypertension. *Biochim Biophys Acta* 2010; **1802**: 1276-1284 [PMID: 20460153 DOI: 10.1016/j.bbadis.2010.05.002]
21. **Yang N**, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. *Nature* 1998; **393**: 809-812 [PMID: 9655398 DOI: 10.1038/31735]
22. **Vardouli L**, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. *J Biol Chem* 2005; **280**: 11448-11457 [PMID: 15647284 DOI: 10.1074/jbc.M402651200]
23. **Matsui T**, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. *J Cell Biol* 1998; **140**: 647-657 [PMID: 9456324 DOI: 10.1083/jcb.140.3.647]
24. **Lockman K**, Hinson JS, Medlin MD, Morris D, Taylor JM, Mack CP. Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors. *J Biol Chem* 2004; **279**: 42422-42430 [PMID: 15292266 DOI: 10.1074/jbc.M405432200]
25. **Olson EN**, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. *Nat Rev Mol Cell Biol* 2010; **11**: 353-365 [PMID: 20414257 DOI: 10.1038/nrm2890]
26. **Laufs U**, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *J Biol Chem* 1998; **273**: 24266-24271 [PMID: 9727051 DOI: 10.1074/jbc.273.37.24266]
27. **Zhou W**, Negash S, Liu J, Raj JU. Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase and myocardin. *Am J Physiol Lung Cell Mol Physiol* 2009; **296**: L780-L789 [PMID: 19251841 DOI: 10.1152/ajplung.90295.2008]
28. **Zhou Q**, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. *Curr Pharm Des* 2009; **15**: 3108-3115 [PMID: 19754385 DOI: 10.2174/138161209789057986]
29. **Wolfrum S**, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. *Arterioscler Thromb Vasc Biol* 2004; **24**: 1842-1847 [PMID: 15319269 DOI: 10.1161/01.ATV.0000142813.33538.82]
30. **Ming XF**, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. *Circulation* 2004; **110**: 3708-3714 [PMID: 15569838 DOI: 10.1161/01.CIR.0000142867.26182.32]
31. **Carlström M**, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. *Physiol Rev* 2015; **95**: 405-511 [PMID: 25834230 DOI: 10.1152/physrev.00042.2012]
32. **Inscho EW**. ATP, P2 receptors and the renal microcirculation. *Purinergic Signal* 2009; **5**: 447-460 [PMID: 19294530 DOI: 10.1007/s11302-009-9147-1]
33. **Yano H**, Hayashi K, Momiyama T, Saga H, Haruna M, Sobue K. Transcriptional regulation of the chicken caldesmon gene. Activation of gizzard-type caldesmon promoter requires a CArG box-like motif. *J Biol Chem* 1995; **270**: 23661-23666 [PMID: 7559534 DOI: 10.1074/jbc.270.40.23661]
34. **Homma K**, Hayashi K, Wakino S, Tokuyama H, Kanda T, Tatematsu S, Hasegawa K, Fujishima S, Hori S, Saruta T, Itoh H. Rho-kinase contributes to pressure-induced constriction of renal microvessels. *Keio J Med* 2014; **63**: 1-12 [PMID: 24429483 DOI: 10.2302/kjm.2013-0001-OA]
35. **Roos MH**, van Rodijnen WF, van Lambalgen AA, ter Wee PM, Tangelder GJ. Renal microvascular constriction to membrane depolarization and other stimuli: pivotal role for rho-kinase. *Pflugers Arch* 2006; **452**: 471-477 [PMID: 16523358 DOI: 10.1007/s00424-006-0053-x]
36. **Shi Y**, Wang X, Chon KH, Cupples WA. Tubuloglomerular feedback-dependent modulation of renal myogenic autoregulation by nitric oxide. *Am J Physiol Regul Integr Comp Physiol* 2006; **290**: R982-R991 [PMID: 16293681 DOI: 10.1152/ajpregu.00346.2005]
37. **Nakamura A**, Hayashi K, Ozawa Y, Fujiwara K, Okubo K, Kanda T, Wakino S, Saruta T. Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. *J Vasc Res* 2003; **40**: 244-251 [PMID: 12902637 DOI: 10.1159/000071888]
38. **Loirand G**, Pacaud P. Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. *Small GTPases* 2014; **5**: 1-10 [PMID: 25496262 DOI: 10.4161/sgtp.28846]
39. **Staruschenko A**, Nichols A, Medina JL, Camacho P, Zheleznova NN, Stockand JD. Rho small GTPases activate the epithelial Na(+) channel. *J Biol Chem* 2004; **279**: 49989-49994 [PMID: 15448132 DOI: 10.1074/jbc.M409812200]
40. **Pochynyuk O**, Medina J, Gamper N, Genth H, Stockand JD, Staruschenko A. Rapid translocation and insertion of the epithelial Na+ channel in response to RhoA signaling. *J Biol Chem* 2006; **281**: 26520-26527 [PMID: 16829523 DOI: 10.1074/jbc.M603716200]
41. **Karpushev AV**, Ilatovskaya DV, Pavlov TS, Negulyaev YA, Staruschenko A. Intact cytoskeleton is required for small G protein dependent activation of the epithelial Na+ channel. *PLoS One* 2010; **5**: e8827 [PMID: 20098689 DOI: 10.1371/journal.pone.0008827]
42. **Hayashi H**, Szászi K, Coady-Osberg N, Furuya W, Bretscher AP, Orlowski J, Grinstein S. Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. *J Gen Physiol* 2004; **123**: 491-504 [PMID: 15078917 DOI: 10.1085/jgp.200308979]
43. **Szászi K**, Kurashima K, Kapus A, Paulsen A, Kaibuchi K, Grinstein S, Orlowski J. RhoA and rho kinase regulate the epithelial Na+/H+ exchanger NHE3. Role of myosin light chain phosphorylation. *J Biol Chem* 2000; **275**: 28599-28606 [PMID: 10893221 DOI: 10.1074/jbc.M001193200]
44. **Nishiki K**, Tsuruoka S, Kawaguchi A, Sugimoto K, Schwartz GJ, Suzuki M, Imai M, Fujimura A. Inhibition of Rho-kinase reduces renal Na-H exchanger activity and causes natriuresis in rat. *J Pharmacol Exp Ther* 2003; **304**: 723-728 [PMID: 12538827 DOI: 10.1124/jpet.102.041871]
45. **Struthers AD**, Dollery CT. Central nervous system mechanisms in blood pressure control. *Eur J Clin Pharmacol* 1985; **28 Suppl**: 3-11 [PMID: 2865146 DOI: 10.1007/BF00543703]
46. **Pilowsky PM**, Goodchild AK. Baroreceptor reflex pathways and neurotransmitters: 10 years on. *J Hypertens* 2002; **20**: 1675-1688 [PMID: 12195099]
47. **Ito K**, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. *Circ Res* 2003; **92**: 1337-1343 [PMID: 12791705 DOI: 10.1161/01.RES.0000079941.59846.D4]
48. **Ito K**, Hirooka Y, Kimura Y, Shimokawa H, Takeshita A. Effects of hydroxyfasudil administered to the nucleus tractus solitarii on blood pressure and heart rate in spontaneously hypertensive rats. *Clin Exp Hypertens* 2005; **27**: 269-277 [PMID: 15835390 DOI: 10.1081/CEH-200048876]
49. **Sagara Y**, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. *J Hypertens* 2007; **25**: 399-406 [PMID: 17211247 DOI: 10.1097/HJH.0b013e328010b87f]
50. **Yamaguchi Y**, Katoh H, Yasui H, Aoki J, Nakamura K, Negishi M. Galpha(12) and galpha(13) inhibit Ca(2+)-dependent exocytosis through Rho/Rho-associated kinase-dependent pathway. *J Neurochem* 2000; **75**: 708-717 [PMID: 10899946 DOI: 10.1046/j.1471-4159.2000.0750708.x]
51. **Salu KJ**, Bosmans JM, Huang Y, Hendriks M, Verhoeven M, Levels A, Cooper S, De Scheerder IK, Vrints CJ, Bult H. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. *Cardiovasc Res* 2006; **69**: 536-544 [PMID: 16386237 DOI: 10.1016/j.cardiores.2005.11.012]
52. **Noma K**, Goto C, Nishioka K, Jitsuiki D, Umemura T, Ueda K, Kimura M, Nakagawa K, Oshima T, Chayama K, Yoshizumi M, Liao JK, Higashi Y. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. *J Am Coll Cardiol* 2007; **49**: 698-705 [PMID: 17291936 DOI: 10.1016/j.jacc.2006.06.082]
53. **Hiley E**, McMullan R, Nurrish SJ. The Galpha12-RGS RhoGEF-RhoA signalling pathway regulates neurotransmitter release in C. elegans. *EMBO J* 2006; **25**: 5884-5895 [PMID: 17139250 DOI: 10.1038/sj.emboj.7601458]
54. **Wei L**, Taffet GE, Khoury DS, Bo J, Li Y, Yatani A, Delaughter MC, Klevitsky R, Hewett TE, Robbins J, Michael LH, Schneider MD, Entman ML, Schwartz RJ. Disruption of Rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved. *FASEB J* 2004; **18**: 857-859 [PMID: 15033930 DOI: 10.1096/fj.03-0664fje]
55. **Yatani A**, Irie K, Otani T, Abdellatif M, Wei L. RhoA GTPase regulates L-type Ca2+ currents in cardiac myocytes. *Am J Physiol Heart Circ Physiol* 2005; **288**: H650-H659 [PMID: 15471984 DOI: 10.1152/ajpheart.00268.2004]
56. **Vlasblom R**, Muller A, Beckers CM, van Nieuw Amerongen GP, Zuidwijk MJ, van Hardeveld C, Paulus WJ, Simonides WS. RhoA-ROCK signaling is involved in contraction-mediated inhibition of SERCA2a expression in cardiomyocytes. *Pflugers Arch* 2009; **458**: 785-793 [PMID: 19294414 DOI: 10.1007/s00424-009-0659-x]
57. **Vahebi S**, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. *Circ Res* 2005; **96**: 740-747 [PMID: 15774859 DOI: 10.1161/01.RES.0000162457.56568.7d]
58. **Draeger A**, Stelzer EH, Herzog M, Small JV. Unique geometry of actin-membrane anchorage sites in avian gizzard smooth muscle cells. *J Cell Sci* 1989; **94 ( Pt 4)**: 703-711 [PMID: 2630565]
59. **Lauriol J**, Keith K, Jaffré F, Couvillon A, Saci A, Goonasekera SA, McCarthy JR, Kessinger CW, Wang J, Ke Q, Kang PM, Molkentin JD, Carpenter C, Kontaridis MI. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis. *Sci Signal* 2014; **7**: ra100 [PMID: 25336613 DOI: 10.1126/scisignal.2005262]
60. **Stepanova OV**, Chadin AV, Masiutin AG, Kulikova TG, Gurin IaV, Sergeeva IA, Shirinskiĭ VP. [Rho-associated protein kinase is involved in establishing the contractile phenotype of cardiomyocytes]. *Biofizika* 2010; **55**: 880-885 [PMID: 21033356]
61. **Bos JL**, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. *Cell* 2007; **129**: 865-877 [PMID: 17540168 DOI: 10.1016/j.cell.2007.05.018]
62. . Aittaleb M, Boguth CA, and Tesmer JJG. Structure and Function of Heterotrimeric G Protein-Regulated Rho Guanine Nucleotide Exchange Factors. Molecular Pharmacology. 2010; 77(2): 111-25. [PMID: PMC2812070 DOI: 10.1124/mol.109.061234]
63. **Yamada T**, Ohoka Y, Kogo M, Inagaki S. Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). *J Biol Chem* 2005; **280**: 19358-19363 [PMID: 15755723 DOI: 10.1074/jbc.M414561200]
64. **Suzuki N**, Nakamura S, Mano H, Kozasa T. Galpha 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. *Proc Natl Acad Sci U S A* 2003; **100**: 733-738 [PMID: 12515866 DOI: 10.1073/pnas.0234057100]
65. **Fukuhara S**, Chikumi H, Gutkind JS. RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? *Oncogene* 2001; **20**: 1661-1668 [PMID: 11313914]
66. **Bregeon J**, Loirand G, Pacaud P, Rolli-Derkinderen M. Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. *Am J Physiol Cell Physiol* 2009; **297**: C1062-C1070 [PMID: 19692654 DOI: 10.1152/ajpcell.00174.2009]
67. **Ying Z**, Jin L, Palmer T, Webb RC. Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells. *Mol Pharmacol* 2006; **69**: 932-940 [PMID: 16354763 DOI: 10.1124/mol.105.017830]
68. **Hilgers RH**, Todd J, Webb RC. Increased PDZ-RhoGEF/RhoA/Rho kinase signaling in small mesenteric arteries of angiotensin II-induced hypertensive rats. *J Hypertens* 2007; **25**: 1687-1697 [PMID: 17620967 DOI: 10.1097/HJH.0b013e32816f778d]
69. **Ying Z**, Giachini FR, Tostes RC, Webb RC. PYK2/PDZ-RhoGEF links Ca2+ signaling to RhoA. *Arterioscler Thromb Vasc Biol* 2009; **29**: 1657-1663 [PMID: 19759375 DOI: 10.1161/ATVBAHA.109.190892]
70. **Artamonov MV**, Momotani K, Stevenson A, Trentham DR, Derewenda U, Derewenda ZS, Read PW, Gutkind JS, Somlyo AV. Agonist-induced Ca2+ sensitization in smooth muscle: redundancy of Rho guanine nucleotide exchange factors (RhoGEFs) and response kinetics, a caged compound study. *J Biol Chem* 2013; **288**: 34030-34040 [PMID: 24106280 DOI: 10.1074/jbc.M113.514596]
71. **Medlin MD**, Staus DP, Dubash AD, Taylor JM, Mack CP. Sphingosine 1-phosphate receptor 2 signals through leukemia-associated RhoGEF (LARG), to promote smooth muscle cell differentiation. *Arterioscler Thromb Vasc Biol* 2010; **30**: 1779-1786 [PMID: 20702813 DOI: 10.1161/ATVBAHA.110.209395]
72. **Guilluy C**, Swaminathan V, Garcia-Mata R, O'Brien ET, Superfine R, Burridge K. The Rho GEFs LARG and GEF-H1 regulate the mechanical response to force on integrins. *Nat Cell Biol* 2011; **13**: 722-727 [PMID: 21572419 DOI: 10.1038/ncb2254]
73. **Rojas RJ**, Yohe ME, Gershburg S, Kawano T, Kozasa T, Sondek J. Galphaq directly activates p63RhoGEF and Trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain. *J Biol Chem* 2007; **282**: 29201-29210 [PMID: 17606614 DOI: 10.1074/jbc.M703458200]
74. **Lutz S**, Shankaranarayanan A, Coco C, Ridilla M, Nance MR, Vettel C, Baltus D, Evelyn CR, Neubig RR, Wieland T, Tesmer JJ. Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. *Science* 2007; **318**: 1923-1927 [PMID: 18096806 DOI: 10.1126/science.1147554]
75. **Wuertz CM**, Lorincz A, Vettel C, Thomas MA, Wieland T, Lutz S. p63RhoGEF--a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells. *FASEB J* 2010; **24**: 4865-4876 [PMID: 20739613 DOI: 10.1096/fj.10-155499]
76. **Momotani K**, Artamonov MV, Utepbergenov D, Derewenda U, Derewenda ZS, Somlyo AV. p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility. *Circ Res* 2011; **109**: 993-1002 [PMID: 21885830 DOI: 10.1161/CIRCRESAHA.111.248898]
77. **Bear MD**, Li M, Liu Y, Giel-Moloney MA, Fanburg BL, Toksoz D. The Lbc Rho guanine nucleotide exchange factor α-catulin axis functions in serotonin-induced vascular smooth muscle cell mitogenesis and RhoA/ROCK activation. *J Biol Chem* 2010; **285**: 32919-32926 [PMID: 20696764 DOI: 10.1074/jbc.M109.062513]
78. **Chikumi H**, Fukuhara S, Gutkind JS. Regulation of G protein-linked guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and LARG by tyrosine phosphorylation: evidence of a role for focal adhesion kinase. *J Biol Chem* 2002; **277**: 12463-12473 [PMID: 11799111 DOI: 10.1074/jbc.M108504200]
79. **Jin L**, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, Webb RC. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. *J Pharmacol Exp Ther* 2006; **318**: 288-295 [PMID: 16569756 DOI: 10.1124/jpet.105.100735]
80. **Cario-Toumaniantz C**, Ferland-McCollough D, Chadeuf G, Toumaniantz G, Rodriguez M, Galizzi JP, Lockhart B, Bril A, Scalbert E, Loirand G, Pacaud P. RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension. *Am J Physiol Cell Physiol* 2012; **302**: C1394-C1404 [PMID: 22322975 DOI: 10.1152/ajpcell.00423.2011]
81. **Ying Z**, Jin L, Dorrance AM, Webb RC. Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. *Am J Hypertens* 2004; **17**: 981-985 [PMID: 15485764 DOI: 10.1016/j.amjhyper.2004.05.006]
82. **Benter IF**, Canatan H, Benboubetra M, Yousif MH, Akhtar S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. *Vascul Pharmacol* 2009; **51**: 101-109 [PMID: 19410658 DOI: 10.1016/j.vph.2009.04.004]
83. **Puetz S**, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. *Physiology (Bethesda)* 2009; **24**: 342-356 [PMID: 19996365 DOI: 10.1152/physiol.00023.2009]
84. **Rittinger K**, Walker PA, Eccleston JF, Smerdon SJ, Gamblin SJ. Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue. *Nature* 1997; **389**: 758-762 [PMID: 9338791 DOI: 10.1038/39651]
85. **Tcherkezian J**, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. *Biol Cell* 2007; **99**: 67-86 [PMID: 17222083 DOI: 10.1042/BC20060086]
86. **Mori K**, Amano M, Takefuji M, Kato K, Morita Y, Nishioka T, Matsuura Y, Murohara T, Kaibuchi K. Rho-kinase contributes to sustained RhoA activation through phosphorylation of p190A RhoGAP. *J Biol Chem* 2009; **284**: 5067-5076 [PMID: 19103606 DOI: 10.1074/jbc.M806853200]
87. **Bai X**, Lenhart KC, Bird KE, Suen AA, Rojas M, Kakoki M, Li F, Smithies O, Mack CP, Taylor JM. The smooth muscle-selective RhoGAP GRAF3 is a critical regulator of vascular tone and hypertension. *Nat Commun* 2013; **4**: 2910 [PMID: 24335996 DOI: 10.1038/ncomms3910]
88. **Hildebrand JD**, Taylor JM, Parsons JT. An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. *Mol Cell Biol* 1996; **16**: 3169-3178 [PMID: 8649427 DOI: 10.1128/MCB.16.6.3169]
89. **Taylor JM**, Macklem MM, Parsons JT. Cytoskeletal changes induced by GRAF, the GTPase regulator associated with focal adhesion kinase, are mediated by Rho. *J Cell Sci* 1999; **112 (Pt 2)**: 231-242 [PMID: 9858476]
90. **Taylor JM**, Hildebrand JD, Mack CP, Cox ME, Parsons JT. Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. *J Biol Chem* 1998; **273**: 8063-8070 [PMID: 9525907 DOI: 10.1074/jbc.273.14.8063]
91. **Doherty JT**, Lenhart KC, Cameron MV, Mack CP, Conlon FL, Taylor JM. Skeletal muscle differentiation and fusion are regulated by the BAR-containing Rho-GTPase-activating protein (Rho-GAP), GRAF1. *J Biol Chem* 2011; **286**: 25903-25921 [PMID: 21622574 DOI: 10.1074/jbc.M111.243030]
92. **Lenhart KC**, Becherer AL, Li J, Xiao X, McNally EM, Mack CP, Taylor JM. GRAF1 promotes ferlin-dependent myoblast fusion. *Dev Biol* 2014; **393**: 298-311 [PMID: 25019370 DOI: 10.1016/j.ydbio.2014.06.025]
93. **Lenhart KC**, O'Neill TJ, Cheng Z, Dee R, Demonbreun AR, Li J, Xiao X, McNally EM, Mack CP, Taylor JM. GRAF1 deficiency blunts sarcolemmal injury repair and exacerbates cardiac and skeletal muscle pathology in dystrophin-deficient mice. *Skelet Muscle* 2015; **5**: 27 [PMID: 26301073 DOI: 10.1186/s13395-015-0054-6]
94. **Ren XR**, Du QS, Huang YZ, Ao SZ, Mei L, Xiong WC. Regulation of CDC42 GTPase by proline-rich tyrosine kinase 2 interacting with PSGAP, a novel pleckstrin homology and Src homology 3 domain containing rhoGAP protein. *J Cell Biol* 2001; **152**: 971-984 [PMID: 11238453 DOI: 10.1083/jcb.152.5.971]
95. **Ehret GB**, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Sõber S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjögren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, Lehtimäki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li Y, Young JH, Bis JC, Kähönen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Bolton JA, Köttgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stančáková A, Raffel LJ, Yao J, Kathiresan S, O'Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT, Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikäinen LP, Soininen P, Tukiainen T, Würtz P, Ong RT, Dörr M, Kroemer HK, Völker U, Völzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK, Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehnke M, Larson MG, Järvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 2011; **478**: 103-109 [PMID: 21909115 DOI: 10.1038/nature10405]
96. **Wain LV**, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M, Rice KM, Henneman P, Smith AV, Ehret GB, Amin N, Larson MG, Mooser V, Hadley D, Dörr M, Bis JC, Aspelund T, Esko T, Janssens AC, Zhao JH, Heath S, Laan M, Fu J, Pistis G, Luan J, Arora P, Lucas G, Pirastu N, Pichler I, Jackson AU, Webster RJ, Zhang F, Peden JF, Schmidt H, Tanaka T, Campbell H, Igl W, Milaneschi Y, Hottenga JJ, Vitart V, Chasman DI, Trompet S, Bragg-Gresham JL, Alizadeh BZ, Chambers JC, Guo X, Lehtimäki T, Kühnel B, Lopez LM, Polašek O, Boban M, Nelson CP, Morrison AC, Pihur V, Ganesh SK, Hofman A, Kundu S, Mattace-Raso FU, Rivadeneira F, Sijbrands EJ, Uitterlinden AG, Hwang SJ, Vasan RS, Wang TJ, Bergmann S, Vollenweider P, Waeber G, Laitinen J, Pouta A, Zitting P, McArdle WL, Kroemer HK, Völker U, Völzke H, Glazer NL, Taylor KD, Harris TB, Alavere H, Haller T, Keis A, Tammesoo ML, Aulchenko Y, Barroso I, Khaw KT, Galan P, Hercberg S, Lathrop M, Eyheramendy S, Org E, Sõber S, Lu X, Nolte IM, Penninx BW, Corre T, Masciullo C, Sala C, Groop L, Voight BF, Melander O, O'Donnell CJ, Salomaa V, d'Adamo AP, Fabretto A, Faletra F, Ulivi S, Del Greco F, Facheris M, Collins FS, Bergman RN, Beilby JP, Hung J, Musk AW, Mangino M, Shin SY, Soranzo N, Watkins H, Goel A, Hamsten A, Gider P, Loitfelder M, Zeginigg M, Hernandez D, Najjar SS, Navarro P, Wild SH, Corsi AM, Singleton A, de Geus EJ, Willemsen G, Parker AN, Rose LM, Buckley B, Stott D, Orru M, Uda M, van der Klauw MM, Zhang W, Li X, Scott J, Chen YD, Burke GL, Kähönen M, Viikari J, Döring A, Meitinger T, Davies G, Starr JM, Emilsson V, Plump A, Lindeman JH, Hoen PA, König IR, Felix JF, Clarke R, Hopewell JC, Ongen H, Breteler M, Debette S, Destefano AL, Fornage M, Mitchell GF, Smith NL, Holm H, Stefansson K, Thorleifsson G, Thorsteinsdottir U, Samani NJ, Preuss M, Rudan I, Hayward C, Deary IJ, Wichmann HE, Raitakari OT, Palmas W, Kooner JS, Stolk RP, Jukema JW, Wright AF, Boomsma DI, Bandinelli S, Gyllensten UB, Wilson JF, Ferrucci L, Schmidt R, Farrall M, Spector TD, Palmer LJ, Tuomilehto J, Pfeufer A, Gasparini P, Siscovick D, Altshuler D, Loos RJ, Toniolo D, Snieder H, Gieger C, Meneton P, Wareham NJ, Oostra BA, Metspalu A, Launer L, Rettig R, Strachan DP, Beckmann JS, Witteman JC, Erdmann J, van Dijk KW, Boerwinkle E, Boehnke M, Ridker PM, Jarvelin MR, Chakravarti A, Abecasis GR, Gudnason V, Newton-Cheh C, Levy D, Munroe PB, Psaty BM, Caulfield MJ, Rao DC, Tobin MD, Elliott P, van Duijn CM. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet* 2011; **43**: 1005-1011 [PMID: 21909110 DOI: 10.1038/ng.922]
97. **Jiang W**, Sordella R, Chen GC, Hakre S, Roy AL, Settleman J. An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression. *Mol Cell* 2005; **17**: 23-35 [PMID: 15629714 DOI: 10.1016/j.molcel.2004.11.024]
98. **Kimura K**, Eguchi S. Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells". *Am J Physiol Cell Physiol* 2009; **297**: C1059-C1061 [PMID: 19741194 DOI: 10.1152/ajpcell.00399.2009]
99. **Haskell MD**, Nickles AL, Agati JM, Su L, Dukes BD, Parsons SJ. Phosphorylation of p190 on Tyr1105 by c-Src is necessary but not sufficient for EGF-induced actin disassembly in C3H10T1/2 fibroblasts. *J Cell Sci* 2001; **114**: 1699-1708 [PMID: 11309200]
100. **Pullikuth AK**, Catling AD. Extracellular signal-regulated kinase promotes Rho-dependent focal adhesion formation by suppressing p190A RhoGAP. *Mol Cell Biol* 2010; **30**: 3233-3248 [PMID: 20439493 DOI: 10.1128/MCB.01178-09]
101. **Lévay M**, Bartos B, Ligeti E. p190RhoGAP has cellular RacGAP activity regulated by a polybasic region. *Cell Signal* 2013; **25**: 1388-1394 [PMID: 23499677 DOI: 10.1016/j.cellsig.2013.03.004]
102. **Gong MC**, Gorenne I, Read P, Jia T, Nakamoto RK, Somlyo AV, Somlyo AP. Regulation by GDI of RhoA/Rho-kinase-induced Ca2+ sensitization of smooth muscle myosin II. *Am J Physiol Cell Physiol* 2001; **281**: C257-C269 [PMID: 11401849]
103. **Shibata S**, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, Kawarazaki W, Takeuchi M, Ayuzawa N, Miyoshi J, Takai Y, Ishikawa A, Shimosawa T, Ando K, Nagase M, Fujita T. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. *J Clin Invest* 2011; **121**: 3233-3243 [PMID: 21765214 DOI: 10.1172/JCI43124]
104. **Li J**, Rohailla S, Gelber N, Rutka J, Sabah N, Gladstone RA, Wei C, Hu P, Kharbanda RK, Redington AN. MicroRNA-144 is a circulating effector of remote ischemic preconditioning. *Basic Res Cardiol* 2014; **109**: 423 [PMID: 25060662 DOI: 10.1007/s00395-014-0423-z]
105. **Artamonov MV**, Jin L, Franke AS, Momotani K, Ho R, Dong XR, Majesky MW, Somlyo AV. Signaling pathways that control rho kinase activity maintain the embryonic epicardial progenitor state. *J Biol Chem* 2015; **290**: 10353-10367 [PMID: 25733666 DOI: 10.1074/jbc.M114.613190]
106. **Chen W**, Chu Y, Zhu D, Yan C, Liu J, Ji K, Gao P. Perivascular gene transfer of dominant-negative N19RhoA attenuates neointimal formation via inhibition of TGF-beta1-Smad2 signaling in rats after carotid artery balloon injury. *Biochem Biophys Res Commun* 2009; **389**: 217-223 [PMID: 19706289 DOI: 10.1016/j.bbrc.2009.08.104]
107. **Boyden LM**, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature* 2012; **482**: 98-102 [PMID: 22266938 DOI: 10.1038/nature10814]
108. **Ibeawuchi SR**, Agbor LN, Quelle FW, Sigmund CD. Hypertension-causing Mutations in Cullin3 Protein Impair RhoA Protein Ubiquitination and Augment the Association with Substrate Adaptors. *J Biol Chem* 2015; **290**: 19208-19217 [PMID: 26100637 DOI: 10.1074/jbc.M115.645358]
109. **Crose LE**, Hilder TL, Sciaky N, Johnson GL. Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. *J Biol Chem* 2009; **284**: 13301-13305 [PMID: 19318350 DOI: 10.1074/jbc.C900009200]
110. **Richardson BT**, Dibble CF, Borikova AL, Johnson GL. Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling. *Biol Chem* 2013; **394**: 35-42 [PMID: 23096573 DOI: 10.1515/hsz-2012-0243]
111. **Aghajanian A**, Wittchen ES, Campbell SL, Burridge K. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif. *PLoS One* 2009; **4**: e8045 [PMID: 19956681 DOI: 10.1371/journal.pone.0008045]
112. **Zuckerbraun BS**, Stoyanovsky DA, Sengupta R, Shapiro RA, Ozanich BA, Rao J, Barbato JE, Tzeng E. Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA. *Am J Physiol Cell Physiol* 2007; **292**: C824-C831 [PMID: 16914531 DOI: 10.1152/ajpcell.00592.2005]
113. **Sandu OA**, Ito M, Begum N. Selected contribution: insulin utilizes NO/cGMP pathway to activate myosin phosphatase via Rho inhibition in vascular smooth muscle. *J Appl Physiol (1985)* 2001; **91**: 1475-1482 [PMID: 11509551]
114. **Sauzeau V**, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. *J Biol Chem* 2000; **275**: 21722-21729 [PMID: 10783386 DOI: 10.1074/jbc.M000753200]
115. **Carretero OA**, Oparil S. Essential hypertension. Part I: definition and etiology. *Circulation* 2000; **101**: 329-335 [PMID: 10645931 DOI: 10.1161/01.CIR.101.3.329]
116. **Mozaffarian D**, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation* 2015; **131**: e29-322 [PMID: 25520374 DOI: 10.1161/CIR.0000000000000152]
117. **Padmanabhan S**, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. *Circ Res* 2015; **116**: 937-959 [PMID: 25767282 DOI: 10.1161/CIRCRESAHA.116.303647]
118. **Pelham CJ**, Ketsawatsomkron P, Groh S, Grobe JL, de Lange WJ, Ibeawuchi SR, Keen HL, Weatherford ET, Faraci FM, Sigmund CD. Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. *Cell Metab* 2012; **16**: 462-472 [PMID: 23040068 DOI: 10.1016/j.cmet.2012.08.011]
119. **Seasholtz TM**, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, Lillie EO, Ziegler MG, Smith DW, Schork NJ, Brown JH, O'Connor DT. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. *Hypertension* 2006; **47**: 937-947 [PMID: 16585408 DOI: 10.1161/01.HYP.0000217364.45622.f0]
120. **Rankinen T**, Church T, Rice T, Markward N, Blair SN, Bouchard C. A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. *Hypertens Res* 2008; **31**: 1651-1657 [PMID: 18971541 DOI: 10.1291/hypres.31.1651]
121. **Liu L**, Cao Y, Cui G, Li Z, Sun J, Zhang L, Chen C, Wang Y, Wang P, Ding H, Wang DW. Association analysis of polymorphisms in ROCK2 with cardiovascular disease in a Chinese population. *PLoS One* 2013; **8**: e53905 [PMID: 23326532 DOI: 10.1371/journal.pone.0053905]
122. **Hashimoto J**, Ito S. Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis. *Ther Adv Cardiovasc Dis* 2009; **3**: 367-378 [PMID: 19574288 DOI: 10.1177/1753944709338942]
123. **Williams B**. Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity--mortality. *J Hypertens* 2012; **30 Suppl**: S13-S18 [PMID: 23124100 DOI: 10.1097/HJH.0b013e328353e523]
124. **Luft FC**. Molecular mechanisms of arterial stiffness: new insights. *J Am Soc Hypertens* 2012; **6**: 436-438 [PMID: 23199674 DOI: 10.1016/j.jash.2012.10.004]
125. **Moody WE**, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. *Heart* 2013; **99**: 365-372 [PMID: 23118349 DOI: 10.1136/heartjnl-2012-302818]
126. **Safar ME**, Nilsson PM. Pulsatile hemodynamics and cardiovascular risk factors in very old patients: background, sex aspects and implications. *J Hypertens* 2013; **31**: 848-857 [PMID: 23449020 DOI: 10.1097/HJH.0b013e32835ed5b9]
127. **Galmiche G**, Labat C, Mericskay M, Aissa KA, Blanc J, Retailleau K, Bourhim M, Coletti D, Loufrani L, Gao-Li J, Feil R, Challande P, Henrion D, Decaux JF, Regnault V, Lacolley P, Li Z. Inactivation of serum response factor contributes to decrease vascular muscular tone and arterial stiffness in mice. *Circ Res* 2013; **112**: 1035-1045 [PMID: 23426017 DOI: 10.1161/CIRCRESAHA.113.301076]
128. **Qiu H**, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, Depre C, Resuello RR, Natividad FF, Hunter WC, Genin GM, Elson EL, Vatner DE, Meininger GA, Vatner SF. Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. *Circ Res* 2010; **107**: 615-619 [PMID: 20634486 DOI: 10.1161/CIRCRESAHA.110.221846]
129. **Liao YC**, Liu PY, Lin HF, Lin WY, Liao JK, Juo SH. Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. *J Mol Cell Cardiol* 2015; **79**: 180-186 [PMID: 25481646 DOI: 10.1016/j.yjmcc.2014.11.023]
130. **Mendelson K**, Evans T, Hla T. Sphingosine 1-phosphate signalling. *Development* 2014; **141**: 5-9 [PMID: 24346695 DOI: 10.1242/dev.094805]
131. **Fenger M**, Linneberg A, Jeppesen J. Network-based analysis of the sphingolipid metabolism in hypertension. *Front Genet* 2015; **6**: 84 [PMID: 25788903 DOI: 10.3389/fgene.2015.00084]
132. **Fenger M**, Linneberg A, Jørgensen T, Madsbad S, Søbye K, Eugen-Olsen J, Jeppesen J. Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension. *BMC Genet* 2011; **12**: 44 [PMID: 21569466 DOI: 10.1186/1471-2156-12-44]
133. **Ren XD**, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. *EMBO J* 1999; **18**: 578-585 [PMID: 9927417 DOI: 10.1093/emboj/18.3.578]
134. **Levy D**, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Köttgen A, Vasan RS, Rivadeneira F, Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O'Donnell CJ, Hofman A, Rotter JI, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van Duijn CM. Genome-wide association study of blood pressure and hypertension. *Nat Genet* 2009; **41**: 677-687 [PMID: 19430479 DOI: 10.1038/ng.384]
135. **Lin Y**, Lai X, Chen B, Xu Y, Huang B, Chen Z, Zhu S, Yao J, Jiang Q, Huang H, Wen J, Chen G. Genetic variations in CYP17A1, CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in She ethnic minority of China. *Atherosclerosis* 2011; **219**: 709-714 [PMID: 21963141 DOI: 10.1016/j.atherosclerosis.2011.09.006]
136. **Citi S**, Pulimeno P, Paschoud S. Cingulin, paracingulin, and PLEKHA7: signaling and cytoskeletal adaptors at the apical junctional complex. *Ann N Y Acad Sci* 2012; **1257**: 125-132 [PMID: 22671598 DOI: 10.1111/j.1749-6632.2012.06506.x]
137. **Endres BT**, Priestley JR, Palygin O, Flister MJ, Hoffman MJ, Weinberg BD, Grzybowski M, Lombard JH, Staruschenko A, Moreno C, Jacob HJ, Geurts AM. Mutation of Plekha7 attenuates salt-sensitive hypertension in the rat. *Proc Natl Acad Sci U S A* 2014; **111**: 12817-12822 [PMID: 25136115 DOI: 10.1073/pnas.1410745111]
138. **GTEx Consortium**. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 2015; **348**: 648-660 [PMID: 25954001 DOI: 10.1126/science.1262110]
139. **Carbone ML**, Brégeon J, Devos N, Chadeuf G, Blanchard A, Azizi M, Pacaud P, Jeunemaître X, Loirand G. Angiotensin II activates the RhoA exchange factor Arhgef1 in humans. *Hypertension* 2015; **65**: 1273-1278 [PMID: 25870189 DOI: 10.1161/HYPERTENSIONAHA.114.05065]
140. **Kanaki AI**, Sarafidis PA, Georgianos PI, Kanavos K, Tziolas IM, Zebekakis PE, Lasaridis AN. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. *Am J Hypertens* 2013; **26**: 608-616 [PMID: 23449607 DOI: 10.1093/ajh/hps098]
141. **Brandes RP**. Statin-mediated inhibition of Rho: only to get more NO? *Circ Res* 2005; **96**: 927-929 [PMID: 15890979 DOI: 10.1161/01.RES.0000168040.70096.2a]
142. **Olson MF**. Applications for ROCK kinase inhibition. *Curr Opin Cell Biol* 2008; **20**: 242-248 [PMID: 18282695 DOI: 10.1016/j.ceb.2008.01.002]
143. **Davies SP**, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem J* 2000; **351**: 95-105 [PMID: 10998351 DOI: 10.1042/bj3510095]
144. **Liao JK**, Seto M, Noma K. Rho kinase (ROCK) inhibitors. *J Cardiovasc Pharmacol* 2007; **50**: 17-24 [PMID: 17666911 DOI: 10.1097/FJC.0b013e318070d1bd]
145. **Asano M**, Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho kinase inhibitor, in strips of small and large mesenteric arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. *Hypertens Res* 2003; **26**: 97-106 [PMID: 12661918 DOI: 10.1291/hypres.26.97]
146. **Uehata M**, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. *Nature* 1997; **389**: 990-994 [PMID: 9353125 DOI: 10.1038/40187]
147. **Surma M**, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. *Future Cardiol* 2011; **7**: 657-671 [PMID: 21929346 DOI: 10.2217/fca.11.51]
148. **Satoh K**, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. *Am J Physiol Heart Circ Physiol* 2011; **301**: H287-H296 [PMID: 21622831 DOI: 10.1152/ajpheart.00327.2011]
149. **Dhaliwal JS**, Badejo AM, Casey DB, Murthy SN, Kadowitz PJ. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. *J Pharmacol Exp Ther* 2009; **330**: 334-341 [PMID: 19369577 DOI: 10.1124/jpet.109.151449]
150. **Doe C**, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP, Willette R, Lee D, Hu E. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. *J Pharmacol Exp Ther* 2007; **320**: 89-98 [PMID: 17018693 DOI: 10.1124/jpet.106.110635]
151. **Boerma M**, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, McGonigle S, Paradise E, Sweetnam P, Fink LM, Vozenin-Brotons MC, Hauer-Jensen M. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. *Blood Coagul Fibrinolysis* 2008; **19**: 709-718 [PMID: 18832915 DOI: 10.1097/MBC.0b013e32830b2891]
152. **Löhn M**, Plettenburg O, Kannt A, Kohlmann M, Hofmeister A, Kadereit D, Monecke P, Schiffer A, Schulte A, Ruetten H, Ivashchenko Y. End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. *World J Cardiol* 2015; **7**: 31-42 [PMID: 25632317 DOI: 10.4330/wjc.v7.i1.31]
153. **Löhn M**, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, Ruetten H. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. *Hypertension* 2009; **54**: 676-683 [PMID: 19597037 DOI: 10.1161/HYPERTENSIONAHA.109.134353]
154. **Carretero OA**, Oparil S. Essential hypertension: part II: treatment. *Circulation* 2000; **101**: 446-453 [PMID: 10653838 DOI: 10.1161/01.CIR.101.4.446]
155. **Epstein M**, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. *Arch Intern Med* 1996; **156**: 1969-1978 [PMID: 8823150 DOI: 10.1001/archinte.1996.00440160081011]
156. **He F**, Luo J, Zhang Z, Luo Z, Fan L, He Y, Wen J, Zhu D, Gao J, Wang Y, Qian Y, Zhou H, Chen X, Zhang W. The RGS2 (-391, C>G) genetic variation correlates to antihypertensive drug responses in Chinese patients with essential hypertension. *PLoS One* 2015; **10**: e0121483 [PMID: 25849301 DOI: 10.1371/journal.pone.0121483]
157. **Vandell AG**, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. *Hypertension* 2012; **60**: 957-964 [PMID: 22949529 DOI: 10.1161/HYPERTENSIONAHA.112.198721]

**P-Reviewer:** Park JB, Stournaras C, Wang J **S-Editor:** Wang JL

**L-Editor: E-Editor:**



**Figure 1 Schematic summarizing RhoA-dependent regulation of vascular smooth muscle contraction and blood pressure homeostasis.** Excitation-contraction coupling in smooth muscle cell (SMC) is mediated by the Ca2+-dependent activation of myosin light chain kinase (MLCK), and SMC tension is directly proportional to myosin light chain (MLC) phosphorylation (p) as this enables myosin’s molecular interaction with actin. SMC contractility is also regulated by GPCR-coupled contractile agonist-mediated activation of the small GTPase RhoA. Downstream activation of Rho kinase (ROCK) inhibits MYPT-1(myosin phosphatase target subunit 1), and results in increased levels of pMLC to promote smooth muscle contraction. RhoA also stimulates G-actin polymerization to filamentous actin (F-actin). Actin polymerization increases SMC tension and stimulates myocardin-related transcription factor (MRTF) nuclear translocation which promotes SRF-dependent transcription of contractile genes. RhoGAPs (such as GRAF3) and RhoGEFs dynamically regulate RhoA activity to achieve blood pressure balance.



**Figure 2 Multi-domain architecture of RhoGEF and RhoGAP proteins known to regulate smooth muscle cell phenotype.** The catalytic domain of RhoGEFs is termed a Dbl homology (DH) domain, which serves as the major binding interface with Rho GTPases and catalyzes the dissociation of GDP from the GTPase. Pleckstrin homology (PH) domains are almost always downstream of the DH domain and these units cooperate to fully activate the GTPase. Other functional domains contained in specific RhoGEFs include the RH (Regulators of G protein Signaling Homology) domain and PDZ (Postsynaptic density 95, disk large, zona occludens-1) domain. RhoGAPs are also multi-domain containing proteins. The RhoGAP domain facilitates GTP hydrolysis and inhibits RhoA activity while other domains can regulate RhoGAP targeting and function. For example, BAR (Bin/amphiphysin/Rvs), PH, or polybasic region (PBR) domains direct lipid binding and promote membrane localization. Other domains are involved in protein-protein interactions such as GTP-binding domain (GBD), diphenylalanine motifs (FF) and the SH3 (SRC Homology 3) domains. The amino acid numbers are shown above each protein are based on the human orthologs (<http://www.ncbi.nlm.nih.gov/>).



**Figure 3 Pharmacologic and genetic regulation of the RhoA signaling axis.** Schematic indicating the sites of action of pharmacological inhibitors (bold) of RhoA signaling molecules. Polymorphisms (SNPs/eQTLs) that could influence RhoA signaling are also shown. AJ: Adherens junction; A2R: Angiotensin type II receptor; ARBs: Angiotensin receptor blockers; ACEIs: Angiotensin converting enzyme (ACE) inhibitors; ASAH1: Acid ceramidase; SPHK1: Sphingosine kinase 1.